***Background.*** Daclatasvir (DCV) is a potent hepatitis C virus (HCV) NS5A replication complex inhibitor with pangenotypic (GT 1-6) activity *in vitro*. Asunaprevir (ASV) is a selective NS3 protease inhibitor with *in vitro* activity against GT 1, 4, 5 and 6. These two direct-acting antivirals (DAA) are in phase 3 development and regulatory review as a dual-DAA regimen (DCV + ASV) for the treatment of HCV GT 1b. DCV and ASV both inhibit P-glycoprotein (P-gp) and individually increase plasma concentrations of the P-gp substrate digoxin (DIG), increasing DIG C~max~ by 65 and 9% and AUC~TAU~ by 27 and 30%, respectively. The combined effect of DCV + ASV on the pharmacokinetics (PK) of DIG was therefore assessed in healthy subjects.

***Methods.*** A single sequence, open-label, one-way interaction study assessed the effect of steady-state DCV (60 mg QD) plus ASV (100 mg BID \[softgel capsule\]) on the PK of single-dose 0.25 mg DIG in healthy subjects. Subjects (N = 16) received DIG on Day 1 and 16, and DCV + ASV on Days 6--20. Serial samples for DIG plasma concentrations were collected up to 120 h postdose on Day 1 and Day 16. Non-compartmental DIG PK parameters were derived. Geometric mean ratios (GMR) and 90% confidence intervals (90%CI) for DIG C~max~ and AUC~inf~ were derived from linear mixed effects models.

***Results.*** All subjects (69% male, aged 23-45 years) completed the study. DCV + ASV dosed with DIG resulted in a 77% increase in DIG C~max~ and a 29% increase in AUC~inf~ (Table). Study drugs were well tolerated; all AEs were mild in intensity except 2 AEs of increased blood creatinine phosphokinase (1 moderate, 1 severe). No AEs were considered study drug-related and all resolved by study end.

                                With DCV+ASV *Adj. Geo. Mean (90%CI)*   W/O DCV+ASV *Adj. Geo. Mean (90%CI)*   GMR *(90%CI)*
  ----------------------------- --------------------------------------- -------------------------------------- ----------------------
  **DIG C~max~***, pg/mL*       1593 (1407, 1803)                       902 (797,1021)                         1.766 (1.504, 2.073)
  **DIG AUC~inf~***, pg×h/mL*   23293 (21522, 25209)                    18090 (15818, 20689)                   1.288 (1.197, 1.385)

***Conclusion.*** DCV and ASV effects on DIG PK are not additive and are similar to DCV alone. Caution is warranted when dosing DCV + ASV with DIG and other P-gp substrates with a narrow therapeutic window; a priori dose modification does not appear to be required. Therapeutic drug monitoring, if available, may be considered.
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